Literature DB >> 11168406

A serpin-induced extensive proteolytic susceptibility of urokinase-type plasminogen activator implicates distortion of the proteinase substrate-binding pocket and oxyanion hole in the serpin inhibitory mechanism.

R Egelund1, T E Petersen, P A Andreasen.   

Abstract

The formation of stable complexes between serpins and their target serine proteinases indicates formation of an ester bond between the proteinase active-site serine and the serpin P1 residue [Egelund, R., Rodenburg, K.W., Andreasen, P.A., Rasmussen, M.S., Guldberg, R.E. & Petersen, T.E. (1998) Biochemistry 37, 6375-6379]. An important question concerning serpin inhibition is the contrast between the stability of the ester bond in the complex and the rapid hydrolysis of the acyl-enzyme intermediate in general serine proteinase-catalysed peptide bond hydrolysis. To answer this question, we used limited proteolysis to detect conformational differences between free urokinase-type plasminogen activator (uPA) and uPA in complex with plasminogen activator inhibitor-1 (PAI-1). Whereas the catalytic domain of free uPA, pro-uPA, uPA in complex with non-serpin inhibitors and anhydro-uPA in a non-covalent complex with PAI-1 was resistant to proteolysis, the catalytic domain of PAI-1-complexed uPA was susceptible to proteolysis. The cleavage sites for four different proteinases were localized in specific areas of the C-terminal beta-barrel of the catalytic domain of uPA, providing evidence that the serpin inhibitory mechanism involves a serpin-induced massive rearrangement of the proteinase active site, including the specificity pocket, the oxyanion hole, and main-chain binding area, rendering the proteinase unable to complete the normal hydrolysis of the acyl-enzyme intermediate. The distorted region includes the so-called activation domain, also known to change conformation on zymogen activation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11168406     DOI: 10.1046/j.1432-1327.2001.01921.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  10 in total

1.  The role of strand 1 of the C beta-sheet in the structure and function of alpha(1)-antitrypsin.

Authors:  S P Bottomley; I D Lawrenson; D Tew; W Dai; J C Whisstock; R N Pike
Journal:  Protein Sci       Date:  2001-12       Impact factor: 6.725

2.  Targeting the autolysis loop of urokinase-type plasminogen activator with conformation-specific monoclonal antibodies.

Authors:  Kenneth A Botkjaer; Sarah Fogh; Erin C Bekes; Zhuo Chen; Grant E Blouse; Janni M Jensen; Kim K Mortensen; Mingdong Huang; Elena Deryugina; James P Quigley; Paul J Declerck; Peter A Andreasen
Journal:  Biochem J       Date:  2011-08-15       Impact factor: 3.857

3.  Thrombin inhibition by serpins disrupts exosite II.

Authors:  Wei Li; Daniel J D Johnson; Ty E Adams; Nicola Pozzi; Vincenzo De Filippis; James A Huntington
Journal:  J Biol Chem       Date:  2010-10-02       Impact factor: 5.157

4.  Serum-stable RNA aptamers to urokinase-type plasminogen activator blocking receptor binding.

Authors:  Daniel Miotto Dupont; Jeppe Buur Madsen; Roland Karl Hartmann; Bertrand Tavitian; Frédéric Ducongé; Jørgen Kjems; Peter André Andreasen
Journal:  RNA       Date:  2010-10-20       Impact factor: 4.942

5.  Targeting tumor cell invasion and dissemination in vivo by an aptamer that inhibits urokinase-type plasminogen activator through a novel multifunctional mechanism.

Authors:  Kenneth A Botkjaer; Elena I Deryugina; Daniel M Dupont; Henrik Gårdsvoll; Erin M Bekes; Cathrine K Thuesen; Zhuo Chen; Zhou Chen; Michael Ploug; James P Quigley; Peter A Andreasen
Journal:  Mol Cancer Res       Date:  2012-10-04       Impact factor: 5.852

6.  Biochemical mechanism of action of a diketopiperazine inactivator of plasminogen activator inhibitor-1.

Authors:  Anja P Einholm; Katrine E Pedersen; Troels Wind; Paulina Kulig; Michael T Overgaard; Jan K Jensen; Julie S Bødker; Anni Christensen; Peter Charlton; Peter A Andreasen
Journal:  Biochem J       Date:  2003-08-01       Impact factor: 3.857

7.  A novel mode of intervention with serine protease activity: targeting zymogen activation.

Authors:  Grant E Blouse; Kenneth A Bøtkjaer; Elena Deryugina; Aleksandra A Byszuk; Janni M Jensen; Kim K Mortensen; James P Quigley; Peter A Andreasen
Journal:  J Biol Chem       Date:  2008-12-01       Impact factor: 5.157

8.  The mosaic receptor sorLA/LR11 binds components of the plasminogen-activating system and platelet-derived growth factor-BB similarly to LRP1 (low-density lipoprotein receptor-related protein), but mediates slow internalization of bound ligand.

Authors:  Jørgen Gliemann; Guido Hermey; Anders Nykjaer; Claus M Petersen; Christian Jacobsen; Peter A Andreasen
Journal:  Biochem J       Date:  2004-07-01       Impact factor: 3.857

9.  Plasminogen activator inhibitor-1 polymers, induced by inactivating amphipathic organochemical ligands.

Authors:  Katrine E Pedersen; Anja P Einholm; Anni Christensen; Lotte Schack; Troels Wind; John M Kenney; Peter A Andreasen
Journal:  Biochem J       Date:  2003-06-15       Impact factor: 3.857

10.  Protein-binding RNA aptamers affect molecular interactions distantly from their binding sites.

Authors:  Daniel M Dupont; Cathrine K Thuesen; Kenneth A Bøtkjær; Manja A Behrens; Karen Dam; Hans P Sørensen; Jan S Pedersen; Michael Ploug; Jan K Jensen; Peter A Andreasen
Journal:  PLoS One       Date:  2015-03-20       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.